Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial

Weiya Z. Wysham*, Elisabeth M. Schaffer, Theresa Coles, Dario R. Roque, Stephanie B. Wheeler, Kenneth H. Kim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial'. Together they form a unique fingerprint.

Medicine & Life Sciences